GlassScriptPhysician profile
Carla D Dirmann
NPI 1851624282
$2,779.94
in general payments reported to CMS, 2019-2025
25 companies · $1,233 in 2025
The $1,233 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $623 · 2022: $132 · 2023: $440 · 2024: $353 · 2025: $1,233.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,025.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,025.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mimedx Group, INC. | $615.22 | 2024-2025 | |
| Novo Nordisk INC | $380.45 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Acera Surgical, INC. | $372.98 | 2021 | |
| Molnlycke Health Care US, LLC | $175.00 | 2025 | Mlnlyckez-Flo Fluidized Positioner, Mepilex, Mextra Superabsorbant |
| Smith+Nephew, INC. | $160.56 | 2021 | |
| Nuo Therapeutics | $147.92 | 2023 | |
| Mayne Pharma Commercial LLC | $139.97 | 2023-2025 | |
| Medtronic, INC. | $108.83 | 2023 | Abre |
| Neurocrine Biosciences, INC. | $95.80 | 2024-2025 | Ingrezza |
| Lilly USA, LLC | $93.14 | 2022-2025 | Mounjaro |
| Next Science LLC | $90.00 | 2023 | Blastx, Surgx, Xperience |
| Reapplix INC. | $89.08 | 2021 | |
| Abbvie INC. | $53.43 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $37.19 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $36.92 | 2024-2025 | Austedo Xr, Austedo Xr |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Reprise Biomedical, INC. | $27.99 | 2025 | Miro3d |
| Organon LLC | $24.29 | 2022 | |
| Lundbeck LLC | $19.28 | 2024 | Rexulti |
| Exact Sciences Corporation | $18.13 | 2023 | Cologuard Collection Kit |
| Mylan Specialty L.P. | $18.09 | 2024 | Yupelri |
| Shield Therapeutics INC | $17.66 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $16.12 | 2022 | |
| Viatris Specialty LLC | $16.09 | 2025 | Yupelri |
| Stryker Corporation | $13.93 | 2025 | Triathlon, Mako |
| Therapeuticsmd, INC. | $11.87 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carla Dirmann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.